The Journal of Practical Medicine >
The detection value of tuberculosis-specific QFT-TB in different types of specimens of tuberculosis patients
Received date: 2023-12-25
Online published: 2024-04-08
Objective The study aimed to compare the diagnostic efficacy of QuantiFERON?TB Gold (QFT?TB) detection of specific cellular immune IGRAs in tuberculosis diagnostic laboratory for pulmonary tuberculosis, extrapulmonary tuberculosis and special population samples in vitro, which may provide evidence for clinical diagnosis and treatment. Methods A total of 546 patients with tuberculosis (AFB + 146 cases, AFB?247 cases), 117 patients with molecular biology positive tuberculosis (Xpert 69 cases, TB?DNA 48 cases) and 36 patients with histopathological positive were collected from January to July 2023. There were 72 cases of extrapulmonary tuberculosis, 276 cases of pleural effusion and 25 cases of ascites. QFT?TB method was used for detection, chi?square test was applied for comparison between groups, and the methodological evaluation of positive rate and coincidence rate were all compared. Results The positive rates of QFT?TB in pulmonary tuberculosis, extrapulmonary tuberculosis and close contacts were 83.69 %, 69.44 %, and 32.41 %, respectively. The coincidence rates of QFT?TB in AFB +, GeneXpert, TB?DNA and pathological confirmed tuberculosis patients were 91.09%, 88.40%, 81.25%, and 72.22%, respectively. The positive rate of pleural effusion in patients with tuberculous pleurisy was 60.50 %, and the uncertainty rate was 29.71%. The positive rate of ascites was 44.00 % and the uncertainty was 36.00%. Conclusion QFT?TB test has good value in the auxiliary diagnosis of pulmonary tuberculosis, and has certain reference significance for the diagnosis of extrapulmonary tuberculosis based on the detection of pleural fluids and ascites.
Key words: pulmonary tuberculosis; IGRAs; QuantiFERON?TB Gold; Gene Xpert
Qi CHEN , Yaxi ZHANG , Mingxia ZHANG , Jieyun ZHANG , Qianting. YANG . The detection value of tuberculosis-specific QFT-TB in different types of specimens of tuberculosis patients[J]. The Journal of Practical Medicine, 2024 , 40(7) : 1002 -1005 . DOI: 10.3969/j.issn.1006-5725.2024.07.021
| 1 | RANGAKA M X, CAVALCANTE S C, MARAIS B J,et al. Chaisson RE: Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection [J]. Lancet, 2015, 386(10010):2344-2353. doi:10.1016/s0140-6736(15)00323-2 |
| 2 | Word Health Organization. Global tuberculosis report 2020 [Z]. Geneva: Word Health Organization, 2020. |
| 3 | VASILIU A, ABELMAN R, KHERABI Y, et al. Landscape of TB Infection and Prevention among People Living with HIV[J]. Pathogens, 2022,11(12):1552. doi:10.3390/pathogens11121552 |
| 4 | 中华人民共和国国家卫生和计划生育委员会, 肺结核诊断( )[S]. 中华人民共和国卫生行业标准, 2017. |
| 5 | KAWATSU L, KANEKO N, IMAHASHI M, et al.Practices and attitudes towards tuberculosis and latent tuberculosis infection screening in people living with HIV/AIDS among HIV physicians in Japan[J]. AIDS Res Ther, 2022,19(1):60. doi:10.1186/s12981-022-00487-8 |
| 6 | XIN H, DU Y, CAO X, et al.Algorithms for Screening for Active Tuberculosis among Individuals with Latent Tuberculosis Infection in a Rural Community in China[J]. Microbiol Spectr, 2022,10(6):e0296722. doi:10.1128/spectrum.02967-22 |
| 7 | 马艳,成诗明. 加速我国结核潜伏感染筛查与预防性治疗的建议[J]. 实用医学杂志, 2023,39(11):1335-1341. doi:10.3969/j.issn.1006-5725.2023.11.003 |
| 8 | 王胜芬,赵雁林. 升级结核病防治策略,提高结核病患者发现水平[J]. 实用医学杂志, 2023,39(11):1331-1334. doi:10.3969/j.issn.1006-5725.2023.11.002 |
| 9 | LIM W S. From latent to active TB: are IGRAs of any use? [J].Thorax, 2016, 71(7):585-586. doi:10.1136/thoraxjnl-2016-208955 |
| 10 | 车洋,柳正卫,李娜,等. 基于GeneXpert MTB/RIF技术的结核病检测策略效果分析[J]. 中国卫生检验杂志, 2023,33(13):1597-1599+1612. |
| 11 | HO J, NGUYEN P T B, NGUYEN T A,et al. Reassessment of the positive predictive value and specificity of Xpert MTB/RIF:a diagnostic accuracy study in the context of community-wide screeing for tuberculosis[J]. Lancet Infect Dis, 2016,16(9):1045-1051. doi:10.1016/s1473-3099(16)30067-6 |
| 12 | NOGUEIRA B M F, KRISHNAN S, BARRETO-DUARTE B, et al. Diagnostic biomarkers for active tuberculosis: progress and challenges[J]. Embo Mol Med, 2022,14(12):e14088. doi:10.15252/emmm.202114088 |
| 13 | DARMAWAN G, LIMAN L M S, HAMIIJOYO L, et al. Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB Gold Plus: a meta-analysis[J]. Clin Chem Lab Med, 2023,61(12):2067-2075. doi:10.1515/cclm-2023-0293 |
| 14 | MATOGA M M, BISSON G P, GUPTA A,et al. Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy[J]. Clin Infect Dis, 2021,73(4):e870-e877. doi:10.1093/cid/ciab179 |
| 15 | TANG Y, YU Y, WANG Q, et al. Evaluation of the IP-10 mRNA release assay for diagnosis of TB in HIV-infected individuals[J]. Front Cell Infect Microbiol, 2023,13:1152665. doi:10.3389/fcimb.2023.1152665 |
| 16 | ORTIZ-BRIZUELA E, APRIANI L, MUKHERJEE T, et al. Assessing the Diagnostic Performance of New Commercial Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis[J]. Clin Infect Dis, 2023,76(11):1989-1999. doi:10.1093/cid/ciad030 |
| 17 | AGUIAR SOARES K, EHRLICH J, CAMARá M,et al. Implementation of WHO guidelines on urine lateral flow LAM testing in high TB/HIV burden African countries[J]. Eur Respir J, 2023,62(4):230056. doi:10.1183/13993003.00556-2023 |
| 18 | BROGER T, KOEPPEL L, HUERGA H, et al. Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data[J]. Lancet Glob Health, 2023,11(6):e903-e916. doi:10.1016/s2214-109x(23)00135-3 |
| 19 | 《中国防痨杂志》编辑委员会, 肺结核活动性判断规范及临床应用专家共识[J]. 中国防痨杂志, 2020, 42(4):301-307. |
/
| 〈 |
|
〉 |